Baxter has snapped up private German biotech SuppreMol and its operations in Munich for 200 million euros.
The move buys Baxter access to SuppreMol’s early-stage development portfolio of novel biologic immune system regulating therapeutics for the treatment of autoimmune diseases.
The pipeline is headed up by SM101, an investigational immunoregulatory therapy that has completed Phase IIa studies in idiopathic thrombocytopenic purpura and systemic lupus erythematosus.
The move builds on Baxter’s existing immunology portfolio, said president of Baxter BioScience Ludwig Hantson, “offering the opportunity to expand into new areas with significant market potential and unmet medical needs in autoimmune diseases”.
